|
2022 Journal Article The PO4-tential for less toxic CAR T-cell therapiesTobin, Joshua W.D., Green, Michael R. and Gandhi, Maher K. (2022). The PO4-tential for less toxic CAR T-cell therapies. Cancer Immunology Research, 10 (12), 1422-1422. doi: 10.1158/2326-6066.cir-22-0793 |
|
2022 Journal Article Diagnosis, management and follow up of peripheral T cell lymphomas: a Consensus Practice Statement from the Australasian Lymphoma AllianceHapgood, G., Latimer, M., Lee, S. T., Kuss, B., Lade, S., Tobin, J. W. D., Purtill, D., Campbell, B. A., Prince, H. M., Hawkes, E. A., Shortt, J. and Radeski, D. (2022). Diagnosis, management and follow up of peripheral T cell lymphomas: a Consensus Practice Statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 52 (10), 1806-1817. doi: 10.1111/imj.15595 |
|
2022 Conference Publication Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin LymphomaGunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17 |
|
2022 Journal Article Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMa, Man Chun John, Tadros, Saber, Bouska, Alyssa, Heavican, Tayla, Yang, Haopeng, Deng, Qing, Moore, Dalia, Akhter, Ariz, Hartert, Keenan, Jain, Neeraj, Showell, Jordan, Ghosh, Sreejoyee, Street, Lesley, Davidson, Marta, Carey, Christopher, Tobin, Joshua, Perumal, Deepak, Vose, Julie M., Lunning, Matthew A., Sohani, Aliyah R., Chen, Benjamin J., Buckley, Shannon, Nastoupil, Loretta J., Davis, R. Eric, Westin, Jason R., Fowler, Nathan H., Parekh, Samir, Gandhi, Maher, Neelapu, Sattva ... Green, Michael R. (2022). Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 107 (3), 690-701. doi: 10.3324/haematol.2020.274258 |
|
2021 Conference Publication DCF: An Efficient and Robust Density-Based Clustering MethodTobin, Joshua and Zhang, Mimi (2021). DCF: An Efficient and Robust Density-Based Clustering Method. 21st IEEE International Conference on Data Mining (IEEE ICDM), Online, 7-10 December 2021. Piscataway, NJ United States: Institute of Electrical and Electronics Engineers. doi: 10.1109/ICDM51629.2021.00074 |
|
2021 Conference Publication The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin LymphomaGunawardana, Jay, Sabdia, Muhammed B., Bednarska, Karolina, Law, Soi C., Brosda, Sandra, Tsang, Hennes, De Long, Lilia Merida, Zaharia, Andreea, Lee, Justina, Jude, Emily, Hawkes, Eliza, Nath, Karthik, Gould, Clare, Burgess, Melinda Lea, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Talaulikar, Dipti, Jain, Sanjiv, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher (2021). The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-145840 |
|
2021 Journal Article Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma AllianceBoyle, Stephen, Tobin, Joshua W. D., Perram, Jacinta, Hamad, Nada, Gullapalli, Veena, Barraclough, Allison, Singaraveloo, Lydia, Han, Min-Hi, Blennerhassett, Richard, Nelson, Niles, Johnston, Anna M., Talaulikar, Dipti, Karpe, Krishna, Bhattacharyya, Abir, Cheah, Chan Yoon, Subramoniapillai, Elango, Bokhari, Waqas, Lee, Cindy, Hawkes, Eliza A., Jabbour, Andrew, Strasser, Simone, Chadban, Steven J., Brown, Christina, Mollee, Peter and Hapgood, Greg (2021). Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma Alliance. HemaSphere, 5 (11) e648, 1-8. doi: 10.1097/hs9.0000000000000648 |
|
2021 Journal Article Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphomaNath, Karthik, Law, Soi-Cheng, Sabdia, Muhammed B., Gunawardana, Jay, de Long, Lilia M., Sester, David, Shanavas, Mohamed, Tsang, Hennes, Tobin, Joshua W. D., Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Jain, Sanjiv, Keane, Colm, Talaulikar, Dipti, Trotman, Judith, Law, Phillip and Gandhi, Maher K. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 5 (12), 2644-2649. doi: 10.1182/bloodadvances.2020004051 |
|
2021 Journal Article Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cellsLaw, Soi C., Hoang, Thanh, O'Rourke, Kacey, Tobin, Joshua W. D., Gunawardana, Jay, Loo‐Oey, Dorothy, Bednarska, Karolina, Merida de Long, Lilia, Sabdia, Muhammed B., Hapgood, Greg, Blyth, Emily, Clancy, Leighton, Hennig, Stefanie, Keane, Colm and Gandhi, Maher K. (2021). Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 21 (10) ajt.16628, 3465-3471. doi: 10.1111/ajt.16628 |
|
2021 Journal Article Discordant solutions to discordant problemsTobin, Joshua W. D. and Gandhi, Maher K. (2021). Discordant solutions to discordant problems. Blood, 137 (21), 2857-2858. doi: 10.1182/blood.2021011362 |
|
2021 Journal Article PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphomaTobin, Joshua W. D., Bednarska, Karolina, Campbell, Ashlea and Keane, Colm (2021). PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphoma. Cells, 10 (5) 1152, 1-23. doi: 10.3390/cells10051152 |
|
2021 Other Outputs A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Crothers, Anna, Eric, Ti, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. doi: 10.1101/2021.03.24.21254220 |
|
2021 Journal Article EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entityGandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520 |
|
2021 Other Outputs Clinical and prognostic tools to improve frontline management strategies in follicular lymphomaTobin, Joshua (2021). Clinical and prognostic tools to improve frontline management strategies in follicular lymphoma. PhD Thesis, Mater Research Institute-UQ, The University of Queensland. doi: 10.14264/5e9fa06 |
|
2021 Journal Article A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaTobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866 |
|
2020 Conference Publication Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphomaTsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954 |
|
2020 Conference Publication A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590 |
|
2020 Journal Article Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphomaGunawardana, Jay, Lee, Justina N., Bednarska, Karolina, Murigneux, Valentine, Long, Lilia Merida, Sabdia, Muhammed B., Birch, Simone, Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma. eJHaem, 1 (2) jha2.116, 517-526. doi: 10.1002/jha2.116 |
|
2020 Journal Article Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?. American Journal of Hematology, 95 (12) ajh.26016, 1454-1456. doi: 10.1002/ajh.26016 |
|
2020 Journal Article Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphomaBararia, Deepak, Hildebrand, Johannes A., Stolz, Sebastian, Haebe, Sarah, Alig, Stefan, Trevisani, Christopher P., Osorio-Barrios, Francisco, Bartoschek, Michael D., Mentz, Michael, Pastore, Alessandro, Gaitzsch, Erik, Heide, Michael, Jurinovic, Vindi, Rautter, Katharina, Gunawardana, Jay, Sabdia, Muhammed B., Szczepanowski, Monika, Richter, Julia, Klapper, Wolfram, Louissaint, Abner, Ludwig, Christina, Bultmann, Sebastian, Leonhardt, Heinrich, Eustermann, Sebastian, Hopfner, Karl-Peter, Hiddemann, Wolfgang, von Bergwelt-Baildon, Michael, Steidl, Christian, Kridel, Robert ... Weigert, Oliver (2020). Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Reports, 31 (5) 107522, 107522. doi: 10.1016/j.celrep.2020.107522 |
